| utidelone IV (UTD1) / Beijing Biostar Technologies |
ChiCTR-TRC-14005100: Phase III Clinical Study of UTD1 Injection in Combination with Capecitabine in Patients With Advanced and Metastatic Breast Cancer |
|
|
| Completed | 3 | 390 | | 30mg UTD1+2000mg Capecitabine ;2500mg Capecitabine | Cancer Hospital, Chinese Academy of Medical Sciences; Level of the institution：, Beijing Biostar Technologies, Ltd. | Advanced and Metastatic Breast Cancer | | | | |
NCT05430399: Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer |
|
|
| Recruiting | 3 | 349 | RoW | utidelone, docetaxel | Sun Yat-sen University, Beijing Biostar Pharmaceuticals Co., Ltd., Hunan Cancer Hospital | Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer | 06/25 | 06/27 | | |
NCT05673590: Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 612 | RoW | Utidelone Injection, Docetaxel Injection | Beijing Biostar Pharmaceuticals Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 06/25 | 12/25 | | |
NCT05673629: Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer |
|
|
| Recruiting | 3 | 552 | RoW | Utidelone Injection in combination with AC, Docetaxel Injection in combination with AC | Beijing Biostar Pharmaceuticals Co., Ltd. | Breast Cancer | 06/25 | 12/25 | | |
NCT05172518: Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer |
|
|
| Not yet recruiting | 3 | 512 | RoW | Taxane plus Intermittent Capecitabine, Utidelone plus Intermittent Capecitabine, Taxane plus Metronomic Capecitabine, Utidelone plus Metronomic Capecitabine | Sun Yat-sen University, Chengdu Biostar | Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer | 03/27 | 03/30 | | |
